Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?

Research output: Contribution to journalReviewResearchpeer-review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{6f4d7b0d4f6f4270a7dc7603f1c986df,
title = "Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?",
abstract = "The use of {"}omics{"} is increasing in research areas looking to identify biomarkers or early preclinical signs of disease or to increase understanding of complex pathological processes that determines prognosis of the disease. Diabetic kidney disease is no exception as it is an area in need of further improvement of both understanding and prognosis. In addition, there is a notion that pretreatment investigations using techniques like proteomics, lipidomics and metabolomics can help individualize therapy thus fulfilling the wish for personalized medicine. An increasing number of cohort studies using these techniques are published, but only few have been validated in external cohorts or even replicated by other groups. In essence, to achieve clinical impact and usefulness, prospective validation is needed. So far, only the urinary proteomics based PRIORITY study has tried to do this, as discussed in this review. Other areas are promising, but are currently lacking such efforts. In this review we report and discuss the current status of urinary proteomics as well as plasma metabolomics and lipidomics with an overview of the results so far, and with some comments and perspectives regarding future developments and implementation. As is evident, these techniques are promising, but there is still some way before widespread clinical use can be foreseen.",
keywords = "Biomarkers, Diabetes, Diabetic kidney disease, Metabolomics, Omics, Proteomics",
author = "Nete Tofte and Frederik Persson and Peter Rossing",
year = "2020",
month = oct,
doi = "10.1007/s40620-020-00759-4",
language = "English",
volume = "33",
pages = "931--948",
journal = "Journal of Nephrology",
issn = "1121-8428",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Omics research in diabetic kidney disease

T2 - new biomarker dimensions and new understandings?

AU - Tofte, Nete

AU - Persson, Frederik

AU - Rossing, Peter

PY - 2020/10

Y1 - 2020/10

N2 - The use of "omics" is increasing in research areas looking to identify biomarkers or early preclinical signs of disease or to increase understanding of complex pathological processes that determines prognosis of the disease. Diabetic kidney disease is no exception as it is an area in need of further improvement of both understanding and prognosis. In addition, there is a notion that pretreatment investigations using techniques like proteomics, lipidomics and metabolomics can help individualize therapy thus fulfilling the wish for personalized medicine. An increasing number of cohort studies using these techniques are published, but only few have been validated in external cohorts or even replicated by other groups. In essence, to achieve clinical impact and usefulness, prospective validation is needed. So far, only the urinary proteomics based PRIORITY study has tried to do this, as discussed in this review. Other areas are promising, but are currently lacking such efforts. In this review we report and discuss the current status of urinary proteomics as well as plasma metabolomics and lipidomics with an overview of the results so far, and with some comments and perspectives regarding future developments and implementation. As is evident, these techniques are promising, but there is still some way before widespread clinical use can be foreseen.

AB - The use of "omics" is increasing in research areas looking to identify biomarkers or early preclinical signs of disease or to increase understanding of complex pathological processes that determines prognosis of the disease. Diabetic kidney disease is no exception as it is an area in need of further improvement of both understanding and prognosis. In addition, there is a notion that pretreatment investigations using techniques like proteomics, lipidomics and metabolomics can help individualize therapy thus fulfilling the wish for personalized medicine. An increasing number of cohort studies using these techniques are published, but only few have been validated in external cohorts or even replicated by other groups. In essence, to achieve clinical impact and usefulness, prospective validation is needed. So far, only the urinary proteomics based PRIORITY study has tried to do this, as discussed in this review. Other areas are promising, but are currently lacking such efforts. In this review we report and discuss the current status of urinary proteomics as well as plasma metabolomics and lipidomics with an overview of the results so far, and with some comments and perspectives regarding future developments and implementation. As is evident, these techniques are promising, but there is still some way before widespread clinical use can be foreseen.

KW - Biomarkers

KW - Diabetes

KW - Diabetic kidney disease

KW - Metabolomics

KW - Omics

KW - Proteomics

UR - http://www.scopus.com/inward/record.url?scp=85085594751&partnerID=8YFLogxK

U2 - 10.1007/s40620-020-00759-4

DO - 10.1007/s40620-020-00759-4

M3 - Review

C2 - 32474762

VL - 33

SP - 931

EP - 948

JO - Journal of Nephrology

JF - Journal of Nephrology

SN - 1121-8428

IS - 5

ER -

ID: 60286817